Table 6.
Concentrations of serum cholesteryl esters (CE), sphingomyelins, diglycerides, triglycerides, and phosphatidylcholines of the study subjects. Data are shown as mean ± standard error (μmol/L).
| Control (n = 26) | IC (n = 24) | CLI (n = 24) | p | |
|---|---|---|---|---|
| CE (16:0) | 168.9 ± 10.3 | 160.2 ± 10.1 | 106.8 ± 10.7 *,† | 0.001 |
| CE (16:1) | 96.6 ± 14.9 | 103.6 ± 14.6 | 69.4 ± 15.5 | 0.281 |
| CE (17:0) | 10.9 ± 0.56 | 9.4 ± 0.55 * | 7.2 ± 0.58 *,† | 0.001 |
| CE (17:1) | 8.82 ± 0.76 | 8.45 ± 0.75 | 5.37 ± 0.79 *,† | 0.007 |
| CE (17:2) | 0.94 ± 0.16 | 0.85 ± 0.15 | 0.49 ± 0.16 | 0.152 |
| CE (18:1) | 244 ± 55 | 422 ± 54 | 302 ± 58 | 0.067 |
| CE (18:2) | 3,015± 176 | 2,791 ± 172 | 1,870 ± 183 *,† | <0.001 |
| CE (18:3) | 119 ± 12.3 | 123.2 ± 12.0 | 83.8 ± 12.7 | 0.069 |
| CE (19:2) | 5.58 ± 0.64 | 5.82 ± 0.63 | 2.69 ± 0.66 *,† | 0.001 |
| CE (19:3) | 0.92 ± 0.266 | 1.86 ± 0.26 * | 0.49 ± 0.277 † | 0.002 |
| CE (20:4) | 911 ± 70 | 892 ± 69 | 662 ± 73 *,† | 0.041 |
| CE (20:5) | 91.9 ± 7.5 | 78.5 ± 7.4 | 59.7 ± 7.8 * | 0.022 |
| CE (22:5) | 43.3 ± 2.5 | 46.2 ± 2.4 | 37.6 ± 2.6 | 0.069 |
| CE (22:6) | 91.3 ± 5.9 | 87.0 ± 5.8 | 71.4 ± 6.2 | 0.078 |
| CE (18:1)/CE (18:2) | 0.084 ± 0.02 | 0.169 ± 0.02 * | 0.186 ± 0.02 * | 0.008 |
| Sphingomyelins | 11.1 ± 0.49 | 10.8 ± 0.48 | 8.80 ± 0.51 *,† | 0.007 |
| Diglycerides | 3.48 ± 0.34 | 4.47 ± 0.33 * | 3.07 ± 0.348 † | 0.014 |
| Triglycerides | 29.1 ± 3.91 | 40.1 ± 3.83 | 27.8 ± 4.06 | 0.055 |
| Lysophosphatidylcholines | 4.13 ± 0.24 | 4.44 ± 0.24 | 2.66 ± 0.25 *,† | 0.001 |
| Phosphatidylcholines | 10.2 ± 0.65 | 12.2 ± 0.63 * | 8.38 ± 0.67 *,† | 0.001 |
Note: The values presented in the column “p-value” represent the overall difference between the three groups; bold font indicates a significant difference between groups (p < 0.05); post-hoc differences in comparisons between individual groups are denoted below as: * = significant difference from non-PAD control, p < 0.05; † = significant difference from IC, p < 0.05.